

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 May 2006 (11.05.2006)

PCT

(10) International Publication Number
WO 2006/050241 A1

(51) International Patent Classification:
A61K 31/473 (2006.01) *A61P 43/00* (2006.01)

92620 (US). **CHEN, June** [US/US]; 28771 Via Los Arboles, San Juan Capistrano, California 92675 (US).

(21) International Application Number:
PCT/US2005/039215

(74) Agents: **JOHNSON, Brent, A.** et al.; C/O Allergan, Inc., 2525 Dupont Drive, Irvine, California 92612 (US).

(22) International Filing Date: 25 October 2005 (25.10.2005)

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/976,442 28 October 2004 (28.10.2004) US

(71) Applicant (*for all designated States except US*): **ALLERGAN, INC.** [US/US]; 2525 Dupont Drive, Irvine, California 92612 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **WHEELER, Larry, A.** [US/US]; 18 Valley View, Irvine, California 92612 (US). **GARST, Michael, E.** [US/US]; 2627 Raqueta, Newport Beach, California 92660 (US). **LIANG, Yanbin** [US/US]; 57 Pacific Crest, Irvine, California 92602 (US). **WOODWARD, David, F.** [GB/US]; 22736 Islamare Lane, Lake Forest, California 92630 (US). **KRAUSS, Achim, H.P.** [DE/US]; 1551 Archer Road, San Marcos, California 92078 (US). **BURK, Robert, M.** [US/US]; 1337 Cerritos Drive, Laguna Beach, California 92651 (US). **DONDE, Yariv** [US/US]; 24386 Antilles Way, Dana Point, California 92629 (US). **HOLOBOSKI, Mark** [US/US]; 29342 Bobolink, Laguna Niguel, California 92677 (US). **OLD, David, W.** [US/US]; 13771 Typee Way, Irvine, California


(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROSTAGLANDIN EP₄ ANTAGONISTS



(57) Abstract: Disclosed herein are methods and compositions related to compound 1 or compound 2: or pharmaceutically acceptable salts, or prodrugs thereof, which are antagonists of a prostaglandin EP₄ receptor, or are prostaglandin EP₄ antagonists.

PROSTAGLANDIN EP₄ ANTAGONISTS

By Inventors

Larry A. Wheeler, Michael E. Garst, Yanbin Liang, David F. Woodward,
Achim H-P. Krauss, Robert M. Burk, Yariv Donde, Mark Holoboski,
David W. Old, and June Chen

BACKGROUND OF THE INVENTION

Field of the Invention

This disclosure relates to pharmaceutical compositions and medical treatments. In particular, this disclosure relates to the use of prostaglandin EP₄ antagonists in said compositions and treatments.

Description of the Related Art

Prostaglandin EP₄ antagonists are believed in the art to have a number of useful medicinal properties. WO0149661 discloses compounds which “strongly bind to PGE₂ receptors (in particular, subtype EP₄), so that the [compounds] are expected to be useful in the prevention and/or treatment of immunopathy, asthma, bone dysplasia, nerve cellular death, lung failure, hepatopathy, acute hepatitis, nephritis, renal failure, hypertension, myocardial ischemia, systemic inflammatory reaction syndrome, septicemia, hemophagocytosis syndrome, macrophage activation syndrome, Still disease, Kawasaki disease, burn, systemic granuloma, ulcerative colitis, Crohn disease, hypercytokinemia at dialysis, multiple organ failure, shock, sleep disorder, platelet aggregation and so on.” WO0149661 also discloses that “compounds which can bind on EP₄ subtype receptor strongly are expected to be useful for the prevention and/or treatment of immunological diseases (autoimmune diseases such as amyotrophic lateral sclerosis (ALS), multiple sclerosis, Sjogren's syndrome,


chronic rheumathrosis and systemic lupus erythematosus etc., and rejection after organ transplantation etc.), asthma, abnormal bone formation, neuronal cell death, lung failure, liver damage, acute hepatitis, nephritis, renal insufficiency, hypertension, myocardial ischemia, systemic inflammatory response syndrome, sepsis, hemophagous syndrome, macrophage activation syndrome, Still's disease, Kawasaki disease, burn, systemic granulomatosis, ulcerative colitis, Crohn's disease, hypercytokinemia at dialysis, multiple organ failure, and shock etc. Further, it is thought that EP₄ subtype receptor relates to sleeping disorder and blood platelet aggregation, so such compounds are expected to be useful for the prevention and/or treatment of these diseases.”

WO0015608 discloses “because of binding strongly to PGE₂ receptors (in particular, subtype EP₄), the compounds [disclosed in the reference] are useful in preventing and/or treating immunologic diseases (autoimmune diseases such as amyotrophic lateral sclerosis (ALS), rejection reactions following organ transplantation, etc.), asthma, bone dysplasia, nerve cell death, lung failure, liver failure, etc. Also, these compounds participate in sleep disorder and platelet agglutination and, therefore, are useful in treating diseases relating thereto.” WO0015608 also discloses “compounds of the present invention of formula (I) bind strongly on subtype EP₄ and therefore are useful for the prophylaxis and/or treatment of immune diseases (autoimmune diseases (amyotrophic lateral sclerosis (ALS), multiple sclerosis, Sjogren's syndrome, arthritis, rheumatoid arthritis, systemic lupus erythematosus, etc.), post-transplantation graft rejection, etc.), asthma, abnormal bone formation, neurocyte death, pulmopathy, hepatopathy, acute hepatitis, nephritis, renal insufficiency, hypertension, myocardial ischemia, systemic inflammatory syndrome, pain induced by ambustion, sepsis, hemophagocytosis syndrome, macrophage activation syndrome, Still's diseases, Kawasaki diseases, burn, systemic granuloma, ulcerative colitis, Crohn's diseases, hypercytokinemia at dialysis, multiple organ failure, shock, etc. They are also related with sleeping disorders and platelet coagulations, and therefore they are thought to be applicable to these diseases.”


In citing the foregoing references, and other references cited herein, applications make no admission as to whether any of said references constitutes prior art. Rather, the determination of what constitutes prior art is a legal decision made on the basis of the dates said references were made available to the public, the authors or inventors of said references, and the effective filing date of the disclosure made herein.

BRIEF DESCRIPTION OF THE INVENTION

Disclosed herein are methods and compositions related to compound 1 or compound 2



Compound 1



Compound 2

or pharmaceutically acceptable salts, or prodrugs thereof (all of which are referred to hereafter, collectively or individually, as "compound 1" or "compound 2", or "compounds"), which are antagonists of a prostaglandin EP₄ receptor, or are prostaglandin EP₄ antagonists.

DETAILED DESCRIPTION OF THE INVENTION

Compounds 1 and 2 are used in a medical sense to treat or prevent a condition or disease which is mediated by a prostaglandin EP₄ receptor.

- 5 A condition or disease which is mediated by the prostaglandin EP₄ receptor is one in which the binding or lack of binding, or the agonism or antagonism of the prostaglandin EP₄ receptor, causes or contributes to the cause of a disease or condition, or a symptom thereof.

- 10 These compounds have several medical uses, including treatment of skeletal disorders, including osteoporosis and bone dysplasia; cancer, including colorectal cancer; immunological disorders, including but not limited to Sjogren's syndrome, multiple sclerosis, amyotrophic lateral sclerosis, rheumatoid arthritis, and lupus erythematosus; neurodegenerative disorders, including stroke; ocular diseases, including dry eye, neurodegenerative
- 15 conditions, glaucoma, non-exudative age related macular degeneration, exudative age related macular degeneration, choroidal neovascularization, acute macular neuroretinopathy, cystoid macular edema, diabetic macular edema, Behcet's disease, diabetic retinopathy, retinal arterial occlusive disease, central retinal vein occlusion, uveitic retinal disease, retinal detachment, trauma,
- 20 conditions caused by laser treatment, conditions caused by photodynamic therapy, photocoagulation, radiation retinopathy, epiretinal membranes, proliferative diabetic retinopathy, branch retinal vein occlusion, anterior ischemic optic neuropathy, non-retinopathy diabetic retinal dysfunction, and retinitis pigmentosa; pulmonary respiratory diseases, including asthma and
- 25 chronic obstructive pulmonary disorder; hepatic diseases including hepatitis; myocardial ischemia; renal disease, including dialysis adjunct and nephritis; systemic hypertension; septicemia; sleep disorders; shock, including multiple organ failure; fibromyalgia; inflammatory bowel disorder; gastrointestinal disease, including irritable bowel syndrome, diarrhea, colitis, ulcerative colitis,
- 30 inflammatory bowel disease; Still's disease; Kawasaki's disease; Crohn's disease; hemophagocytosis syndrome; dermatological disorders, including

dermatitis, psoriasis, and acne; systemic granuloma; burns and scalds; pain, including migraine; and antipyrexia.

In one embodiment these compounds are used to treat or prevent skeletal disorders including osteoporosis and bone dysplasia.

5 In another embodiment these compounds are used to treat or prevent cancer including colorectal cancer.

In another embodiment these compounds are used to treat or prevent immunological disorders, including but not limited to Sjogren's syndrome, multiple sclerosis, amyotrophic lateral sclerosis, rheumatoid arthritis, and lupus
10 erythematosus.

In another embodiment these compounds are used to treat or prevent neurodegenerative disorders, including stroke.

In another embodiment these compounds are used to treat or prevent ocular diseases including dry eye, and glaucoma.

15 In another embodiment these compounds are used for neuroprotection in an ocular disease such as glaucoma, non-exudative age related macular degeneration, exudative age related macular degeneration, choroidal neovascularization, acute macular neuroretinopathy, cystoid macular edema, diabetic macular edema, Behcet's disease, diabetic retinopathy, retinal arterial
20 occlusive disease, central retinal vein occlusion, uveitic retinal disease, retinal detachment, trauma, conditions caused by laser treatment, conditions caused by photodynamic therapy, photocoagulation, radiation retinopathy, epiretinal membranes, proliferative diabetic retinopathy, branch retinal vein occlusion, anterior ischemic optic neuropathy, non-retinopathy diabetic retinal
25 dysfunction, and retinitis pigmentosa.

In another embodiment these compounds are used to treat or prevent pulmonary respiratory diseases such as asthma and chronic obstructive pulmonary disorder.

In another embodiment these compounds are used to treat or prevent
30 hepatic diseases including hepatitis.

In another embodiment these compounds are used to treat or prevent myocardial ischemia.

In another embodiment these compounds are used to treat or prevent renal disease including use as a dialysis adjunct and the treatment or prevention of nephritis.

5 In another embodiment these compounds are used to treat or prevent systemic hypertension.

In another embodiment these compounds are used to treat or prevent septicemia.

In another embodiment these compounds are used to treat or prevent sleep disorders.

10 In another embodiment these compounds are used to treat or prevent shock including multiple organ failure.

In another embodiment these compounds are used to treat or prevent fibromyalgia.

15 In another embodiment these compounds are used to treat or prevent gastrointestinal disease, including irritable bowel syndrome, diarrhea, colitis, inflammatory bowel disease, and ulcerative colitis.

In another embodiment these compounds are used to treat or prevent Still's disease.

20 In another embodiment these compounds are used to treat or prevent Kawasaki's disease.

In another embodiment these compounds are used to treat or prevent Crohn's disease.

In another embodiment these compounds are used to treat or prevent hemophagocytosis syndrome.

25 In another embodiment these compounds are used to treat or prevent dermatological disorders including dermatitis, psoriasis, and acne.

In another embodiment these compounds are used to treat or prevent systemic granuloma

30 In another embodiment these compounds are used to treat burns and scalds.

In another embodiment these compounds are used to treat or prevent pain.

In another embodiment these compounds are used to treat or prevent antipyrexia.

Compositions, formulations, dosage forms, medicaments, kits, and pharmaceutical products comprising compound 1 for the medical uses described
5 herein are also contemplated.

A "pharmaceutically acceptable salt" is any salt that retains the activity of the parent compound and does not impart any additional deleterious or untoward effects on the subject to which it is administered and in the context in which it is administered compared to the parent compound.

10 Pharmaceutically acceptable salts of acidic functional groups may be derived from organic or inorganic bases. The salt may be a mono or polyvalent ion. Of particular interest are the inorganic ions, lithium, sodium, potassium, calcium, and magnesium. Organic salts may be made with amines, particularly ammonium salts such as mono-, di- and trialkyl amines or ethanol amines. Salts
15 may also be formed with caffeine, tromethamine and similar molecules. Hydrochloric acid or some other pharmaceutically acceptable acid may form a salt with a compound that includes a basic group, such as an amine or a pyridine ring.

A "prodrug" is a compound which is converted to a therapeutically
20 active compound after administration, and the term should be interpreted as broadly herein as is generally understood in the art. While not intending to limit the scope of the invention, conversion may occur by hydrolysis of an ester group or some other biologically labile group. Generally, but not necessarily, a prodrug is inactive or less active than the therapeutically active compound to
25 which it is converted.

Those skilled in the art will readily understand that for administration the compounds disclosed herein can be admixed with pharmaceutically acceptable excipients which, per se, are well known in the art. Specifically, a drug to be administered systemically, it may be confectioned as a powder, pill,
30 tablet or the like, or as a solution, emulsion, suspension, aerosol, syrup or elixir suitable for oral or parenteral administration or inhalation.

For solid dosage forms, non-toxic solid carriers include, but are not limited to, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, the polyalkylene glycols, talcum, cellulose, glucose, sucrose and magnesium carbonate. The solid dosage forms may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in the U.S. Pat. Nos. 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release. Liquid pharmaceutically administrable dosage forms can, for example, comprise a solution or suspension of one or more of the presently useful compounds and optional pharmaceutical adjutants in a carrier, such as for example, water, saline, aqueous dextrose, glycerol, ethanol and the like, to thereby form a solution or suspension. If desired, the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like. Typical examples of such auxiliary agents are sodium acetate, sorbitan monolaurate, triethanolamine, sodium acetate, triethanolamine oleate, etc. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 16th Edition, 1980. The composition of the formulation to be administered, in any event, contains a quantity of one or more of the presently useful compounds in an amount effective to provide the desired therapeutic effect.

Parenteral administration is generally characterized by injection, either subcutaneously, intramuscularly or intravenously. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol and the like. In addition, if desired, the injectable pharmaceutical compositions to be administered may also contain minor amounts of non-toxic auxiliary

substances such as wetting or emulsifying agents, pH buffering agents and the like.

The amount of the presently useful compound or compounds administered is, of course, dependent on the therapeutic effect or effects desired, on the specific mammal being treated, on the severity and nature of the mammal's condition, on the manner of administration, on the potency and pharmacodynamics of the particular compound or compounds employed, and on the judgement of the prescribing physician. The therapeutically effective dosage of the presently useful compound or compounds is preferably in the range of about 0.5 ng/kg/day or about 1 ng/kg/day to about 100 mg/kg/day.

For ophthalmic application, solutions are often prepared using a physiological saline solution as a major vehicle. Ophthalmic solutions should preferably be maintained at a comfortable pH with an appropriate buffer system. The formulations may also contain conventional, pharmaceutically acceptable preservatives, stabilizers and surfactants.

Preservatives that may be used in the pharmaceutical compositions of the present invention include, but are not limited to, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric acetate and phenylmercuric nitrate. A useful surfactant is, for example, Tween 80. Likewise, various useful vehicles may be used in the ophthalmic preparations of the present invention. These vehicles include, but are not limited to, polyvinyl alcohol, povidone, hydroxypropyl methyl cellulose, poloxamers, carboxymethyl cellulose, hydroxyethyl cellulose and purified water.

Tonicity adjustors may be added as needed or convenient. They include, but are not limited to, salts, particularly sodium chloride, potassium chloride, mannitol and glycerin, or any other suitable ophthalmically acceptable tonicity adjustor.

Various buffers and means for adjusting pH may be used so long as the resulting preparation is ophthalmically acceptable. Accordingly, buffers include acetate buffers, citrate buffers, phosphate buffers and borate buffers. Acids or bases may be used to adjust the pH of these formulations as needed.

In a similar vein, an ophthalmically acceptable antioxidant for use in the present invention includes, but is not limited to, sodium metabisulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole and butylated hydroxytoluene.

5 Other excipient components which may be included in the ophthalmic preparations are chelating agents. A useful chelating agent is edentate disodium, although other chelating agents may also be used in place or in conjunction with it.

The ingredients are usually used in the following amounts:

10	<u>Ingredient</u>	<u>Amount (% w/v)</u>
	active ingredient	about 0.001-5
	preservative	0-0.10
	vehicle	0-40
	tonicity adjustor	1-10
15	buffer	0.01-10
	pH adjustor	q.s. pH 4.5-7.5
	antioxidant	as needed
	surfactant	as needed
	purified water	as needed to make 100%

20

For topical use, creams, ointments, gels, solutions or suspensions, etc., containing the compound disclosed herein are employed. Topical formulations may generally be comprised of a pharmaceutical carrier, cosolvent, emulsifier, penetration enhancer, preservative system, and emollient.

25 The actual dose of the active compounds of the present invention depends on the specific compound, and on the condition to be treated; the selection of the appropriate dose is well within the knowledge of the skilled artisan.

The following Examples describe methods of synthesizing the compounds
30 shown herein to be a prostaglandin EP₄ antagonist. Other methods may also be used.

These compounds can be purchased from several companies including ChemDiv., Inc, San Diego, CA; Interchim, Muntlucon, Cedex, 03103, France; Ambinter, Paris, France; and ChemBridge Corporation, San Diego, CA.

Determination of the effect of compound 1 on the activity of Prostaglandin E2 on the induced calcium signal: HEK-293(EBNA) cells, stably expressing cDNAs for the human EP₄ receptor and Gqs5 proteins, were seeded at a density of 5×10^4 cells per well in Biocoat® Poly-D-lysine-coated black-wall, clear-bottom 96-well plates (Becton-Dickinson) and allowed to attach overnight in an incubator at 37°C. Cells were then washed twice with HBSS-HEPES buffer (Hanks Balanced Salt Solution without bicarbonate and phenol red, 20 mM HEPES, pH 7.4) using a Denley Cellwash plate washer (Labsystems; Franklin, MA). After 45-60 min of dye-loading in the dark using the calcium-sensitive dye Fluo-4 AM, at a final concentration of 2 μ M, plates were washed four times with HBSS-HEPES buffer to remove excess dye and leaving 100 μ l buffer in each well. Plates were then placed into a FLIPR™ instrument and were allowed to equilibrate at 37°C. Drug solution was added in a 50 μ l volume to each well to give the desired final concentration. Cells were excited with an Argon laser at 488 nm, and emission was measured through a 510-570 nm bandwidth emission filter (FLIPR™, Molecular Devices, Sunnyvale, CA). The peak increase in fluorescence intensity was recorded for each well. On each plate, the standard agonist Prostaglandin E2 was tested over a 10^{-11} to 10^{-5} molar concentration range in the presence of vehicle or test drug. Concentration-effects were measured for Prostaglandin E2 in the presence of vehicle and test drug. A similar analysis was carried out for the other prostaglandin receptors, and for compound 2. The results are presented in Table 1, with the standard agonist for each assay listed in the Table.

Table 1

Compound	hDP (HEK)	hEP1 (HEK)	hEP2 (HEK)	hEP3A (HEK)	hEP4 (HEK)	hFP (HEK)	hIP (HEK)	hTP (HEK)
Standard agonist	6 (BW245C)	0.3 (PGE ₂)	2.5 (PGE ₂)	0.2 (PGE ₂)	0.2 (PGE ₂)	4.3 (PGF _{2α})	62 (Carba-cyclin)	0.3 (U-46619)
Compound 1	NA (K _B)	NA (K _B)	NA (K _B)	NA (K _B)	101 (K _B)	NA (K _B)	NA (K _B)	NA (K _B)
Compound 2	NA (K _B)	NA (K _B)	NA (K _B)	NA (K _B)	172 (K _B)	NA (K _B)	NA (K _B)	NA (K _B)

hDP, hEP₂ and hEP₄ expressing cells coexpress chimeric G_{qs5}
hEP_{3A} expressing cells coexpress chimeric G_{qi5}
NA: not active (at 10 μM); (% efficacy) for partial agonist; K_B values are for
5 antagonists (nM)

Example 24

A nasal spray comprising compound 1 is administered to a patient 5
times per day until the symptoms subside.

10

Example 25

A capsule comprising compound 2 is administered daily to a patient
suffering from osteoporosis. Increase in bone density or reduction in bone
density loss occurs for as long as the patient continues treatment.

15

Example 26

A tablet comprising compound 2 is administered to a person suffering
from a migraine headache. Significantly less pain is experienced by the patient.

20

Example 27

A capsule or suppository comprising compound 1 is administered daily
to a patient suffering from cancer. Improvement in the patient's condition
25 occurs.


30

The present invention is not to be limited in scope by the exemplified
embodiments, which are intended as illustrations of individual aspects of the
invention. Indeed, various modifications of the invention in addition to those
shown and described herein will become apparent to those skilled in the art
from the foregoing description. Such modifications are intended to fall within
the scope of appended claims.

CLAIMS

What is claimed is:


1. A method comprising
a compound represented by



- or a pharmaceutically acceptable salt or a prodrug thereof,
to a mammal suffering from, or at risk of developing, a prostaglandin EP₄
receptor mediated condition or disease.
- 10 2. The method of claim 1 wherein said EP₄ receptor mediated condition or
disease is selected from the group consisting of skeletal disorders, osteoporosis,
bone dysplasia, cancer, colorectal cancer, immunological disorders, Sjogren's
syndrome, multiple sclerosis, amyotrophic lateral sclerosis, rheumatoid arthritis,
lupus erythematosus, stroke, ocular diseases, dry eye, neurodegenerative
15 conditions, glaucoma, non-exudative age related macular degeneration,
exudative age related macular degeneration, choroidal neovascularization, acute
macular neuroretinopathy, cystoid macular edema, diabetic macular edema,
Behcet's disease, diabetic retinopathy, retinal arterial occlusive disease, central
retinal vein occlusion, uveitic retinal disease, retinal detachment, trauma,
20 conditions caused by laser treatment, conditions caused by photodynamic
therapy, photocoagulation, radiation retinopathy, epiretinal membranes,
proliferative diabetic retinopathy, branch retinal vein occlusion, anterior
ischemic optic neuropathy, non-retinopathy diabetic retinal dysfunction, retinitis
pigmentosa, pulmonary respiratory diseases, asthma, chronic obstructive

- pulmonary disorder, hepatic diseases hepatitis, myocardial ischemia, renal disease, nephritis, systemic hypertension, septicemia, sleep disorders, shock, multiple organ failure, fibromyalgia, gastrointestinal disease, irritable bowel syndrome, diarrhea, colitis, ulcerative colitis, Still's disease, Kawasaki's
- 5 disease, Crohn's disease, inflammatory bowel disease, hemophagocytosis syndrome, dermatological disorders, dermatitis, psoriasis, acne, systemic granuloma, burns, scalds, pain, migraine, and antipyrexia.
3. The method of claim 1 wherein said EP₄ receptor mediated condition or disease is a skeletal disorder.
- 10 4. The method of claim 1 wherein said EP₄ receptor mediated condition or disease is cancer.
5. The method of claim 1 wherein said EP₄ receptor mediated condition or disease is an immunological disorder.
6. The method of claim 1 wherein said EP₄ receptor mediated condition or
- 15 disease is a neurodegenerative disorder.
7. The method of claim 1 wherein said EP₄ receptor mediated condition or disease is an ocular disease.
8. The method of claim 1 wherein said EP₄ receptor mediated condition or disease is a pulmonary respiratory disease.
- 20 9. The method of claim 1 wherein said EP₄ receptor mediated condition or disease is a hepatic disease.
10. The method of claim 1 wherein said EP₄ receptor mediated condition or disease is a myocardial ischemia.
11. The method of claim 1 wherein said EP₄ receptor mediated condition or
- 25 disease is a renal disease.
12. The method of claim 1 wherein said EP₄ receptor mediated condition or disease is a systemic hypertension.
13. The method of claim 1 wherein said EP₄ receptor mediated condition or disease is a septicemia.
- 30 14. The method of claim 1 wherein said EP₄ receptor mediated condition or disease is a sleep disorder.

15. The method of claim 1 wherein said EP₄ receptor mediated condition or disease is a shock condition.
16. The method of claim 1 wherein said EP₄ receptor mediated condition or disease is a fibromyalgia
- 5 17. The method of claim 1 wherein said EP₄ receptor mediated condition or disease is a gastrointestinal disease.
18. The method of claim 1 wherein said EP₄ receptor mediated condition or disease is Still's disease.
19. The method of claim 1 wherein said EP₄ receptor mediated condition or
10 disease is Kawasaki's disease.
20. The method of claim 1 wherein said EP₄ receptor mediated condition or disease is Crohn's disease.
21. The method of claim 1 wherein said EP₄ receptor mediated condition or
disease is inflammatory bowel disease.
- 15 22. The method of claim 1 wherein said EP₄ receptor mediated condition or disease is colitis.
23. The method of claim 1 wherein said EP₄ receptor mediated condition or disease is a hemophagocytosis syndrome.
24. The method of claim 1 wherein said EP₄ receptor mediated condition or
20 disease is a dermatological disorder.
25. The method of claim 1 wherein said EP₄ receptor mediated condition or disease is a systemic granuloma
26. The method of claim 1 wherein said EP₄ receptor mediated condition or disease is a treat burn or a scald.
- 25 27. The method of claim 1 wherein said EP₄ receptor mediated condition or disease is pain.
28. The method of claim 1 wherein said EP₄ receptor mediated condition or disease is an antipyrexia.
29. The method of claim 1 wherein said EP₄ receptor mediated condition is
30 a dermatological disorder.
30. A pharmaceutical product comprising




or a pharmaceutically acceptable salt or a prodrug thereof;

wherein said product is packaged and labeled for the treatment or prevention of

- 5 a disease or condition selected from the group consisting of skeletal disorders, osteoporosis, bone dysplasia, cancer, colorectal cancer, immunological disorders, Sjogren's syndrome, multiple sclerosis, amyotrophic lateral sclerosis, rheumatoid arthritis, lupus erythematosus, stroke, ocular diseases, dry eye, neurodegenerative conditions, glaucoma, non-exudative age related
- 10 macular degeneration, exudative age related macular degeneration, choroidal neovascularization, acute macular neuroretinopathy, cystoid macular edema, diabetic macular edema, Behcet's disease, diabetic retinopathy, retinal arterial occlusive disease, central retinal vein occlusion, uveitic retinal disease, retinal detachment, trauma, conditions caused by laser treatment, conditions caused by
- 15 photodynamic therapy, photocoagulation, radiation retinopathy, epiretinal membranes, proliferative diabetic retinopathy, branch retinal vein occlusion, anterior ischemic optic neuropathy, non-retinopathy diabetic retinal dysfunction, retinitis pigmentosa, pulmonary respiratory diseases, asthma, chronic obstructive pulmonary disorder, hepatic diseases hepatitis, myocardial
- 20 ischemia, renal disease, nephritis, systemic hypertension, septicemia, sleep disorders, shock, multiple organ failure, fibromyalgia, gastrointestinal disease, irritable bowel syndrome, diarrhea, colitis, ulcerative colitis, Still's disease, Kawasaki's disease, Crohn's disease, inflammatory bowel disease,

hemophagocytosis syndrome, dermatological disorders, dermatitis, psoriasis, systemic granuloma, burns, scalds, pain, migraine, and antipyrexia.

31. A method comprising
treating or preventing a condition or disease selected from the group consisting
5 of skeletal disorders, osteoporosis, bone dysplasia, cancer, colorectal cancer, immunological disorders, Sjogren's syndrome, multiple sclerosis, amyotrophic lateral sclerosis, rheumatoid arthritis, lupus erythematosus, stroke, ocular diseases, dry eye, neurodegenerative conditions, glaucoma, non-exudative age related macular degeneration, exudative age related macular degeneration,
10 choroidal neovascularization, acute macular neuroretinopathy, cystoid macular edema, diabetic macular edema, Behcet's disease, diabetic retinopathy, retinal arterial occlusive disease, central retinal vein occlusion, uveitic retinal disease, retinal detachment, trauma, conditions caused by laser treatment, conditions caused by photodynamic therapy, photocoagulation, radiation retinopathy,
15 epiretinal membranes, proliferative diabetic retinopathy, branch retinal vein occlusion, anterior ischemic optic neuropathy, non-retinopathy diabetic retinal dysfunction, retinitis pigmentosa, pulmonary respiratory diseases, asthma, chronic obstructive pulmonary disorder, hepatic diseases hepatitis, myocardial ischemia, renal disease, nephritis, systemic hypertension, septicemia, sleep
20 disorders, shock, multiple organ failure, fibromyalgia, gastrointestinal disease, irritable bowel syndrome, diarrhea, colitis, ulcerative colitis, Still's disease, Kawasaki's disease, Crohn's disease, inflammatory bowel disease, hemophagocytosis syndrome, dermatological disorders, dermatitis, psoriasis, systemic granuloma, burns, scalds, pain, migraine, and antipyrexia;
25 by administering to a mammal suffering from said condition or disease a compound comprising



or a pharmaceutically acceptable salt or a prodrug thereof.

INTERNATIONAL SEARCH REPORT

International application No

PC17/US2005/039215

A. CLASSIFICATION OF SUBJECT MATTER

A61K31/473 A61P43/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, EMBASE, BIOSIS, PAJ, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DATABASE CHEMCATS STN; AN: 2003:2283722 25 April 2003 (2003-04-25), XP002368290 RN: 468093-78-9 the whole document	1-31
A	DATABASE REGISTRY STN; RN: 468093-79-0 31 October 2002 (2002-10-31), XP002368291 the whole document	1-31
A	DATABASE REGISTRY STN; RN: 468713-77-1 1 November 2002 (2002-11-01), XP002368292 the whole document	1-31
-/--		



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

17 February 2006

Date of mailing of the international search report

09/03/2006

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Herrera, S

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2005/039215

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DATABASE REGISTRY STN; RN: 339310-56-4 4 June 2001 (2001-06-04), XP002368293 the whole document -----	1-31